A randomized controlled trial enhancing viral hepatitis testing in primary care via digital crowdsourced intervention
- PMID: 35853995
- PMCID: PMC9296450
- DOI: 10.1038/s41746-022-00645-2
A randomized controlled trial enhancing viral hepatitis testing in primary care via digital crowdsourced intervention
Abstract
Despite the availability of hepatitis B virus (HBV) and hepatitis C virus (HCV) testing in primary care, testing rates in China remain low. Social media is an inexpensive means of disseminating information and could facilitate hepatitis testing promotion. We evaluated the capacity of digitally crowdsourced materials to promote HBV/HCV testing uptake via a randomized controlled trial (identifier: ChiCTR1900025771), which enrolled 750 Chinese primary care patients. We randomized patients (1:1) to receive crowdsourced HBV/HCV promotion materials through social media or facility-based care without promotional materials for four weeks. Exposure to all intervention materials was associated with increased odds of HBV (aOR = 1.79, 95% CI: 1.09-3.00) and HCV (aOR = 1.95, 95% CI: 1.29-2.99) testing compared to facility-based care. There was a significant reduction in hepatitis stigma among intervention group participants (HBV slope: -0.15, p < 0.05; and HCV slope: -0.13, p < 0.05). Digitally crowdsourced promotion messages could enhance hepatitis testing uptake and should be considered in hepatitis reduction strategies.Trial registration: Chinese Clinical Trial Registry (ChiCTR1900025771) on September 9, 2019. Available from: http://www.chictr.org.cn/showproj.aspx?proj=42788.
© 2022. The Author(s).
Conflict of interest statement
P.C. is a staff member of the World Health Organization; the author alone is responsible for the views expressed in this publication, and they do not necessarily represent the decisions or policies of the World Health Organization. W.K. Seto received speaker’s fees from AstraZeneca and Mylan, is an advisory board member of Abbott, is an advisory board member and received speaker’s fees from AbbVie, and is an advisory board member, received speaker’s fees and researching funding from Gilead Sciences. The remaining authors declare no competing interests.
Figures
References
-
- World Health Organization. World Hepatitis Day 2019: Invest in eliminating hepatitis. Available from: https://www.who.int/campaigns/world-hepatitis-day/2019. Accessed 3rd September, 2021. (2020).
-
- World Health Organization. Hepatitis in China. Available from: https://www.who.int/china/health-topics/hepatitis. Accessed January 13th, 2022.
Grants and funding
LinkOut - more resources
Full Text Sources
